News & Updates
Showing Pharmacy articles
Showing
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.
OLE data FORTIFY risankizumab role in Crohn’s disease
Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
Generic antiobesity drugs viable after successful weight loss with GLP-1 RA
Older-generation generic antiobesity medications (AOMs) for weight maintenance may be prescribed to patients who have achieved successful weight loss with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, suggests a study.
Baseline IOP predicts treatment response for SLT, PGA drops
Primary treatment with either selective laser trabeculoplasty (SLT) or prostaglandin analog (PGA) drops for ocular hypertension and open-angle glaucoma results in a decrease in intraocular pressure (IOP), and this benefit is greater with higher baseline IOP, a study has shown.